The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Annals of Surgical Oncology

• Publication date

  2020-06-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1245/s10434-020-08530-6PMID 32591951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

  2019cited by this paper
• CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.

  2019cited by this paper
• Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

  2019cited by this paper
• Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication

  2019cited by this paper
• Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer

  2019cited by this paper
• Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration

  2019cited by this paper
• Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

  2018cited by this paper
• Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

  2018cited by this paper
• Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

  2017cited by this paper
• Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study

  2017cited by this paper
• 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

  2017cited by this paper
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

  2017cited by this paper
• Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

  2017cited by this paper
• How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study

  2016cited by this paper
• Abstract CT092: A phase II study of neoadjuvant abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (neoMONARCH)

  2016cited by this paper
• 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

  2016cited by this paper
• Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy

  2016cited by this paper
• The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancer.

  2015cited by this paper
• Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.

  2015cited by this paper
• Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

  2014cited by this paper
• Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).

  2014cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.

  2013cited by this paper
• Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

  2013cited by this paper
• Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

  2013cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

  2012cited by this paper
• Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.

  2012cited by this paper
• Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

  2012cited by this paper
• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  2011cited by this paper
• Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

  2011cited by this paper
• Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

  2008cited by this paper
• Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer

  2007cited by this paper
• Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

  2007cited by this paper
• Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus).

  2006cited by this paper
• Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

  2005cited by this paper
• Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

  2005cited by this paper
• Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.

  2005cited by this paper
• Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer.

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Pathobiology of preoperative chemotherapy

  2002cited by this paper
• Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.

  2002cited by this paper
• Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer

  2002cited by this paper
• Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.

  2001cited by this paper
• Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.

  2000cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

  1999cited by this paper
• Letrozole as Primary Medical Therapy for Locally Advanced and Large Operable Breast Cancer

  1998cited by this paper
• Prognostic and predictive factors in breast cancer by immunohistochemical analysis.

  1998cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1982cited by this paper
• Reporting results of cancer treatment

  1981cited by this paper
• WHO Handbook for Reporting Results of Cancer Treatment

  1980cited by this paper
• Complement-Fixation Reaction of Human Neoplastic Tissue with Sera From Hamsters Bearing Virus-Induced Tumors.∗

  1967cited by this paper

• Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer

  2025cites this paper
• Current Concepts and Controversies in Post-Neoadjuvant Breast Pathology.

  2025cites this paper
• Characterizing the General Surgery Experience of Future Breast Surgeons: A Multi-institutional Study from the US ROPE Consortium

  2025cites this paper
• Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery.

  2024cites this paper
• NESS Commentary for 2022-1305.

  2023cites this paper
• Management of the axilla in postmenopausal patients with cN0 hormone receptor-positive/HER2-negative breast cancer treated with neoadjuvant endocrine therapy and its prognostic impact

  2023cites this paper
• Lasting Impacts of the COVID-19 Pandemic on Breast Cancer Diagnosis and Treatment in the United States

  2023cites this paper
• Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer

  2023cites this paper
• Neoadjuvant Therapy in Breast Cancer: Histologic Changes and Clinical Implications.

  2022cites this paper
• The use of neoadjuvant therapy increases the rate of breast conservation in men with locally advanced breast cancer.

  2022cites this paper
• The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells

  2022cites this paper
• How we treat HR-positive, HER2-negative early breast cancer.

  2022cites this paper
• Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning

  2021cites this paper
• Is breast surgery time critical when neo‐adjuvant therapy is not appropriate?

  2021cites this paper
• Delays in operative management of early-stage, estrogen receptor–positive breast cancer during the COVID-19 pandemic: A multi-institutional matched historical cohort study

  2021cites this paper
• Surgical Considerations and Expectations in Patients Receiving Neoadjuvant Chemotherapy and Neoadjuvant Endocrine Therapy

  2021cites this paper
• Neoadjuvant approach in patients with early breast cancer evaluation of the breast cancer patient (patient assessment, staging, planning)

  2021cites this paper
• Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic

  2021cites this paper
• Discussion

  2011cites this paper